Trial Profile
A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3041658 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Feb 2017
Price :
$35
*
At a glance
- Drugs Eltrekibart (Primary) ; Eltrekibart (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 14 Feb 2017 Status changed from recruiting to completed.
- 25 Aug 2016 Planned End Date changed from 1 Oct 2016 to 1 Feb 2017.
- 15 Jun 2016 Planned End Date changed from 1 Dec 2015 to 1 Oct 2016.